OVERVIEW
StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications.
BUSINESS
We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology.
TECHNOLOGY
Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells.
StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications.
BUSINESS
We are currently focused on scale-up activities for our patented core technology, bone marrow – High Performance Microenvironment (BM-HPME™) and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology.
TECHNOLOGY
Our core novel technology platform is an advanced stem cell culture system – HPME™ – High Performance MicroEnvironment. BM-HPME™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells.
Location: United States, Texas, San Antonio
Employees: 11-50
Phone: +1 210-877-9323
Total raised: $8M
Founded date: 2010
Investors 2
| Date | Name | Website |
| - | Fountainhe... | fountainhe... |
| - | Targeted T... | targetedte... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.04.2015 | - | $8M | - |
Mentions in press and media 6
| Date | Title | Description |
| 05.08.2015 | Ten Life Sciences Companies to Watch in Central Texas | |
| 14.04.2015 | StemBioSys of San Antonio Lands $8 Million in Funding | StemBioSys, which focuses on research with adult stem cells, has closed on $8 million in Series A funding. |
| 25.07.2013 | Texas stem cell tech company raises $2.3 million, seeks $5.6 more | According to the company website, the “centerpiece” of its expansion is the “XC-marrow ECM™, a patented “extracellular matrix” laid down by human bone marrow mesenchymal stem cells (MSCs)–a 3D microenvironment that allows stem cells to repl... |
| 21.02.2013 | Texas biotech rounds up $2 million for platform to grow stem cells faster | The company says its three-dimensional extracellular matrix can grow cells quicker than conventional media while retaining stem cell properties and may help overcome key obstacles in creating stem cell therapies. The technology was develope... |
| - | Texas biotech rounds up $2 million for platform to grow stem cells faster | A University of Texas spinoff company has pulled in $2 million to test a new technique for culturing non-embryonic stem cells. According to a regulatory filing, StemBioSys raised at least $2 million of a $3.5 million equity offering. A comp... |
| - | Texas stem cell tech company raises $2.3 million, seeks $5.6 more | StemBioSys, a San Antonio company that manufactures and develops stem cell technologies in the regenerative medicine field, has landed $2,377,802. It still seeks $5,622,198, according to the regulatory filing. The company is in a quiet peri... |